Phibro Animal Health (PAHC) Stock

Phibro (PAHC) possesses solid growth attributes, which could help it handily outperform the market.

Phibro (PAHC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Investors looking for stocks in the Medical - Products sector might want to consider either Phibro Animal Health (PAHC) or Abbott (ABT). But which of these two stocks offers value investors a better bang for their buck right now?

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its first quarter ended September 30, 2024, and its updated financial guidance for the year ending June 30, 2025. Highlights for the three months ended September 30, 2024 (compared to the three months ended September 30, 2023) Net sales of $260.4 million, an increase of $29.1 million, or 13% Net income of $7.0 million, an increase of $15.0 million Dil.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Phibro successfully acquires Zoetis Inc.'s MFA portfolio and certain water-soluble products.

The stocks we learn to search for today are top-ranked momentum stocks that might be worth buying to close out October and throughout the last two months of 2024.

Investors interested in Medical - Products stocks are likely familiar with Phibro Animal Health (PAHC) and Insulet (PODD). But which of these two stocks is more attractive to value investors?